Research recommendations coming out of this guidance Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital? Dose strategies for people who are obese:- What is the clinical and cost effectiveness of weight-based dose-adjustment strategies of lowmolecular-weight heparin (LMWH) compared with fixed-dose strategies of LMWH for preventing VTE in people who are very obese (BMI over 35) who are admitted to hospital or having day procedures (including surgery and chemotherapy)? Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation? Aspirin prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur:- What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur? Duration of prophylaxis for elective total hip replacement surgery:- What is the clinical and cost effectiveness of standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement surgery?
Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?
Dose strategies for people who are obese:- What is the clinical and cost effectiveness of weight-based dose-adjustment strategies of lowmolecular-weight heparin (LMWH) compared with fixed-dose strategies of LMWH for preventing VTE in people who are very obese (BMI over 35) who are admitted to hospital or having day procedures (including surgery and chemotherapy)?
Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation?
Aspirin prophylaxis for people with fragility fractures of the pelvis, hip or proximal femur:- What is the clinical and cost effectiveness of aspirin alone versus other pharmacological and/or mechanical prophylaxis strategies (alone or in combination) for people with fragility fractures of the pelvis, hip or proximal femur?
Duration of prophylaxis for elective total hip replacement surgery:- What is the clinical and cost effectiveness of standard versus extended duration pharmacological prophylaxis for preventing VTE in people undergoing elective total hip replacement surgery?